Autres langues Supernus Pharmaceuticals, Inc.

Actions

SUPN

US8684591089

Produits pharmaceutiques

Temps réel estimé Cboe BZX 15:47:31 01/10/2026			Varia. 5j.	Varia. 1 janv.
43,05 ^USD	+0,02%		-0,65%	-13,46%

25/09	Addex récupère son portefeuille de modulateurs GABAB	AW
17/09	Indivior fixe un dividende exceptionnel de 8,13 $ par action sous réserve de la finalisation de la fusion avec Supernus	MT

Autres langues

28/09	Addex bringt Programme im zweiten Quartal weiter voran
25/09	Addex-Chef sieht Rückgabe von GABAB-Programm positiv
25/09	Addex erhält Rechte an GABAB-Portfolio von Indivior zurück
24/09	Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
24/09	Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
17/09	Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger
02/09	Supernus Pharmaceuticals to Participate in September Investor Conferences
31/08	Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
07/08	Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
03/08	Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2026
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Timothy C. Dec as Chief Financial Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Member of the Board of the Supernus, Inc
03/08	Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Supernus, Indivior merge to strengthen neuroscience drug portfolio
03/08	Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
03/08	Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised
03/08	Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger
03/08	Supernus: Q2 Earnings Snapshot
03/08	Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, vs. FactSet Est of $205.3M
03/08	Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, vs. FactSet Est of $0.04 EPS
03/08	Supernus Announces Second Quarter 2026 Financial Results
03/08	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
22/07	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
14/07	Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD